MCID: INF002
MIFTS: 27

Inflammatory Diarrhea malady

Categories: Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Inflammatory Diarrhea

Aliases & Descriptions for Inflammatory Diarrhea:

Name: Inflammatory Diarrhea 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050132

Summaries for Inflammatory Diarrhea

Disease Ontology : 12 A gastrointestinal system infectious disease involving diarrhea that occurs when there is damage to the mucosal lining or brush border, which leads to a passive loss of protein-rich fluids, and a decreased ability to absorb these lost fluids. It can be caused by bacterial infections, viral infections, parasitic infections, or autoimmune problems such as inflammatory bowel diseases. It can also be caused by tuberculosis, colon cancer, and enteritis.

MalaCards based summary : Inflammatory Diarrhea is related to diarrhea and oculogyric crisis. An important gene associated with Inflammatory Diarrhea is PITX1 (Paired Like Homeodomain 1), and among its related pathways/superpathways are Toll Comparative Pathway and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Sucralfate and Basiliximab have been mentioned in the context of this disorder. Affiliated tissues include colon, and related phenotype is digestive/alimentary.

Related Diseases for Inflammatory Diarrhea

Diseases in the Diarrhea family:

Diarrhea 7 Diarrhea 6
Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity Inflammatory Diarrhea
Acute Diarrhea Congenital Diarrhea

Diseases related to Inflammatory Diarrhea via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 diarrhea 10.0
2 oculogyric crisis 10.0 FUT2 PITX1
3 colon adenocarcinoma 9.9 CXCL8 FUT2
4 atrophy of prostate 9.7 CXCL8 SLC9A3
5 typhoid fever 9.6 CXCL8 PITX1 SLC9A3
6 kawasaki disease 9.5
7 cholera 9.5
8 acute diarrhea 9.1 CXCL8 FUT2 PITX1 SLC9A3 SPI1 VIPR1

Graphical network of the top 20 diseases related to Inflammatory Diarrhea:



Diseases related to Inflammatory Diarrhea

Symptoms & Phenotypes for Inflammatory Diarrhea

MGI Mouse Phenotypes related to Inflammatory Diarrhea:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 8.92 FUT2 PITX1 SLC9A3 VIPR1

Drugs & Therapeutics for Inflammatory Diarrhea

Drugs for Inflammatory Diarrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 349)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sucralfate Approved Phase 4 54182-58-0
2
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
3
Cyclosporine Approved, Investigational, Vet_approved Phase 4 79217-60-0, 59865-13-3 5284373 6435893
4
Everolimus Approved Phase 4 159351-69-6 6442177
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3 24280-93-1 446541
9
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
11
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
12
Ciprofloxacin Approved, Investigational Phase 4,Phase 2 85721-33-1 2764
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
14
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 63006 5281004
15
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
16
Colchicine Approved Phase 4 64-86-8 6167 2833
17
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
18
Lenograstim Approved Phase 4,Phase 1 135968-09-1
19
Diphenhydramine Approved Phase 4,Phase 1 58-73-1, 147-24-0 3100
20
Dopamine Approved Phase 4,Phase 1 51-61-6, 62-31-7 681
21
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
22
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1 75614-87-8, 51-45-6 774
23
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
24
Ondansetron Approved Phase 4 99614-02-5 4595
25
Promethazine Approved Phase 4,Phase 1 60-87-7 4927
26
Ranitidine Approved Phase 4,Phase 1 66357-59-3, 66357-35-5 3001055
27
Zinc Approved Phase 4,Phase 3,Phase 1 7440-66-6 32051 23994
28
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
29
Copper Approved Phase 4 15158-11-9, 7440-50-8 27099
30
Iron Approved Phase 4,Phase 2 7439-89-6 23925
31
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
32
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
33
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
35
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 54575, 6560146 143
36
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
38
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 1 114977-28-5 148124 9877265
39 Anticholesteremic Agents Phase 4,Phase 1
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
42 Atorvastatin Calcium Phase 4 134523-03-8
43 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2
44 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 1
45 Hypolipidemic Agents Phase 4,Phase 2,Phase 1
46 Lipid Regulating Agents Phase 4,Phase 2,Phase 1
47 Antacids Phase 4,Phase 2,Phase 1
48 Anti-Ulcer Agents Phase 4,Phase 2,Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 185)
id Name Status NCT ID Phase
1 Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging Unknown status NCT00920101 Phase 4
2 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4
3 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
4 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4
5 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
6 Effect of Probiotics on Intestinal Bacterial Population and Immune Modulation Completed NCT00763399 Phase 4
7 Effect of Probiotics (Bio-Three) in Children's Enterocolitis Completed NCT00463190 Phase 4
8 Prevention of Acute Radiation Enteritis With Glutamine Completed NCT00828399 Phase 4
9 Colchicine Or Naproxen Treatment for ACute gouT Completed NCT01994226 Phase 4
10 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4
11 Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
12 The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726) Completed NCT00359216 Phase 4
13 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4
14 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4
15 A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma Completed NCT02233803 Phase 4
16 Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product Completed NCT00291382 Phase 4
17 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Recruiting NCT02774057 Phase 4
18 Clinical Study of Artz in the Treatment of Knee Osteoarthritis Recruiting NCT02826031 Phase 4
19 An Efficacy and Safety Study of Infliximab in Pediatric Participants With Inflammatory Bowel Disease Recruiting NCT02566889 Phase 4
20 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Recruiting NCT02728063 Phase 4
21 Mortality Reduction After Oral Azithromycin: Morbidity Study Recruiting NCT02048007 Phase 4
22 Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma Active, not recruiting NCT02113436 Phase 4
23 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4
24 Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma Terminated NCT01070888 Phase 4
25 Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant Terminated NCT00596947 Phase 4
26 Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome Withdrawn NCT02190526 Phase 4
27 Long-Term Treatment of Collagenous Colitis With Budesonide Unknown status NCT00139165 Phase 3
28 Saccharomyces Boulardii in Irritable Bowel Syndrome Completed NCT00589771 Phase 3
29 Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children Completed NCT00560222 Phase 3
30 Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis Completed NCT00151892 Phase 3
31 Zinc Supplementation in Shigella Patients Completed NCT00321126 Phase 3
32 Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy Completed NCT01198145 Phase 3
33 Trial of Mesalamine for the Treatment of Active Microscopic Colitis Completed NCT00952952 Phase 2, Phase 3
34 Emollients in the Management of Atopic Dermatitis Completed NCT01779258 Phase 3
35 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Completed NCT01243671 Phase 3
36 Myfortic vs. Cellcept in Kidney Transplant Recipients Completed NCT00533624 Phase 2, Phase 3
37 Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation Completed NCT00128739 Phase 3
38 Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED) Completed NCT00381485 Phase 3
39 Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED) Completed NCT00383552 Phase 3
40 A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01817764 Phase 3
41 A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01822899 Phase 3
42 Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED) Completed NCT00383240 Phase 3
43 A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Diseas Completed NCT01706328 Phase 3
44 A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02345161 Phase 3
45 Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis Completed NCT00579878 Phase 3
46 Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Completed NCT02502734 Phase 3
47 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Completed NCT00405756 Phase 3
48 Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis Completed NCT00450086 Phase 3
49 Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma Completed NCT02139644 Phase 3
50 A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Completed NCT00420849 Phase 3

Search NIH Clinical Center for Inflammatory Diarrhea

Genetic Tests for Inflammatory Diarrhea

Anatomical Context for Inflammatory Diarrhea

MalaCards organs/tissues related to Inflammatory Diarrhea:

39
Colon

Publications for Inflammatory Diarrhea

Articles related to Inflammatory Diarrhea:

id Title Authors Year
1
Inflammatory diarrhea due to enteroaggregative Escherichia coli: evidence from clinical and mice model studies. ( 24294997 )
2013
2
Serum C-reactive protein (CRP) levels in young adults can be used to discriminate between inflammatory and non-inflammatory diarrhea. ( 22926497 )
2013
3
Human enteroids: preclinical models of non-inflammatory diarrhea. ( 24564938 )
2013
4
Diarrhea. Enterotoxigenic Bacteroides fragilis: newly recognized cause of inflammatory diarrhea. ( 19678432 )
2009
5
Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. ( 18680416 )
2008
6
Dangers of empiric oral ciprofloxacin in the treatment of acute inflammatory diarrhea in children. ( 11734755 )
2001
7
Mechanisms of inflammatory diarrhea. ( 1634090 )
1992
8
Clinical and immunologic significance of cholera-like toxin and cytotoxin production by Campylobacter species in patients with acute inflammatory diarrhea in the USA. ( 2760498 )
1989
9
Kawasaki disease presenting in an adult as inflammatory diarrhea. ( 3509115 )
1987

Variations for Inflammatory Diarrhea

Expression for Inflammatory Diarrhea

Search GEO for disease gene expression data for Inflammatory Diarrhea.

Pathways for Inflammatory Diarrhea

Pathways related to Inflammatory Diarrhea according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.45 CXCL8 SPI1
2 11.34 CXCL8 SLC9A3 VIPR1
3 10.71 CXCL8 SPI1 VIPR1

GO Terms for Inflammatory Diarrhea

Molecular functions related to Inflammatory Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor binding GO:0001085 8.62 PITX1 SPI1

Sources for Inflammatory Diarrhea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....